Virtus ETF Advisers LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 158 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.

Quarter-by-quarter ownership
Virtus ETF Advisers LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$468,543
+48.4%
25,272
-11.5%
0.28%
+52.4%
Q2 2023$315,652
+14.0%
28,540
+38.4%
0.19%
+23.0%
Q1 2023$276,900
+10.5%
20,618
+1.8%
0.15%
+16.0%
Q4 2022$250,505
-21.2%
20,251
-5.3%
0.13%
-6.4%
Q3 2021$318,000
-31.8%
21,387
-8.4%
0.14%
-27.1%
Q2 2021$466,000
+4.3%
23,353
+20.5%
0.19%
+1.6%
Q1 2021$447,000
-4.1%
19,375
+2.8%
0.19%
-2.1%
Q4 2020$466,000
+44.7%
18,849
+142.5%
0.19%
+14.2%
Q3 2020$322,000
-5.6%
7,774
+9.2%
0.17%
+5.0%
Q2 2020$341,000
+4.9%
7,119
+38.1%
0.16%
+20.1%
Q1 2020$325,000
-53.1%
5,156
-7.8%
0.13%
+18.6%
Q4 2019$693,000
+19.9%
5,591
-35.8%
0.11%
-2.6%
Q3 2019$578,000
-28.6%
8,711
-14.4%
0.12%
-32.2%
Q2 2019$810,000
+1.5%
10,180
+42.6%
0.17%
-89.9%
Q1 2019$798,000
+42.5%
7,138
+28.4%
1.70%
+1668.8%
Q4 2018$560,000
-53.9%
5,560
-42.2%
0.10%
-23.8%
Q3 2018$1,215,000
+61.4%
9,618
+7.2%
0.13%
-81.1%
Q2 2018$753,000
-16.6%
8,970
-38.9%
0.67%
-14.9%
Q1 2018$903,000
-0.6%
14,681
-5.5%
0.78%
-31.3%
Q4 2017$908,000
+84.2%
15,542
+82.8%
1.14%
+1625.8%
Q3 2017$493,000
-52.1%
8,5010.0%0.07%
-57.1%
Q2 2017$1,029,000
-8.4%
8,501
-14.3%
0.15%
-23.0%
Q1 2017$1,123,000
+15.2%
9,925
+10.6%
0.20%
-31.3%
Q4 2016$975,000
+35.2%
8,971
+104.9%
0.29%
-16.6%
Q3 2016$721,000
+32.1%
4,378
+14.4%
0.35%
-13.8%
Q2 2016$546,000
+177.2%
3,826
+149.3%
0.40%
+49.4%
Q1 2016$197,0001,5350.27%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2021
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders